Company News

Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids

Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids Sonata Treatment provides patients with an incision-free, outpatient option with exceptional results and fast recovery Redwood City, Calif. – September 3, 2020 – Gynesonics®, a women’s [...]

2020-09-07T16:05:33+01:00September 3rd, 2020|All News, Company News|

Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System

Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System Redwood City, Calif. – August 20, 2020 – Gynesonics, [...]

2020-09-07T16:02:12+01:00August 20th, 2020|All News, Company News|

Relievant announces publication of 5-Year data demonstrating long-term clinical benefits of the Intracept procedure in chronic low back pain patients

Relievant announces publication of 5-Year data demonstrating long-term clinical benefits of the Intracept procedure in chronic low back pain patients MINNEAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) -- Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal [...]

2020-06-08T17:33:59+01:00June 8th, 2020|All News, Company News|

SOPHiA GENETICS Expands its Executive Team, Naming Lara Hashimoto Chief Business Officer

SOPHiA GENETICS Expands its Executive Team, Naming Lara Hashimoto Chief Business Officer Lausanne, Switzerland, and Boston, United States, April 8, 2020 - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be [...]

2020-04-28T14:21:15+01:00April 9th, 2020|All News, Company News|

IntelyCare Launches First COVID-19 Training Program for Nurses, Nursing Facilities to Help Mitigate Spread of Virus

IntelyCare Launches First COVID-19 Training Program for Nurses, Nursing Facilities to Help Mitigate Spread of Virus Free Virtual Training Offered to Meet Growing Demand from Most Vulnerable Healthcare Segment for Increased Education and Support QUINCY, MA – March 17, 2020 – In response to the global COVID-19 pandemic, [...]

2020-03-18T16:12:31+00:00March 18th, 2020|All News, Company News|

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth Geneva, February 20, 2020 - Endeavour Vision led the Series B funding round for Boston-based IntelyCare, along with Kaiser Permanente Ventures and Generator Ventures, allowing the company to [...]

2020-02-20T18:22:04+00:00February 20th, 2020|All News, Company News|

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage Endeavour Vision, Kaiser Permanente Ventures, and Generator Ventures Join Existing Investors in Round, Leveraging Gig Economics to Close Projected 1 Million Nurse Shortfall by 2030; Builds on Company’s Exceptional Momentum QUINCY, MA – February [...]

2020-02-20T14:06:24+00:00February 20th, 2020|All News, Company News|

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinical stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug [...]

2020-01-06T14:14:02+00:00January 6th, 2020|All News, Company News|
Go to Top